BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17276501)

  • 1. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
    Villedieu M; Briand M; Duval M; Héron JF; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 May; 105(2):373-84. PubMed ID: 17276501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK.
    Zhu H; Zhang L; Wu S; Teraishi F; Davis JJ; Jacob D; Fang B
    Oncogene; 2004 Jun; 23(29):4984-92. PubMed ID: 15122344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
    Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
    Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol.
    Wu S; Zhu H; Gu J; Zhang L; Teraishi F; Davis JJ; Jacob DA; Fang B
    Cancer Res; 2004 Feb; 64(3):1110-3. PubMed ID: 14871845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment.
    Villedieu M; Deslandes E; Duval M; Héron JF; Gauduchon P; Poulain L
    Gynecol Oncol; 2006 Jun; 101(3):507-19. PubMed ID: 16387351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
    Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
    Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
    Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
    Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proliferation inhibition and apoptosis onset in human ovarian carcinoma cell line SKOV3 induced by Genistein].
    Li Y; Mi C
    Ai Zheng; 2003 Jun; 22(6):586-91. PubMed ID: 12948406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.
    Kafara P; Icard P; Guillamin M; Schwartz L; Lincet H
    J Ovarian Res; 2015 Jun; 8():36. PubMed ID: 26063499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
    DeHaan RD; Yazlovitskaya EM; Persons DL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
    Yasmeen A; Beauchamp MC; Piura E; Segal E; Pollak M; Gotlieb WH
    Gynecol Oncol; 2011 Jun; 121(3):492-8. PubMed ID: 21388661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis.
    Mohan N; Banik NL; Ray SK
    Cancer Biol Ther; 2011 Nov; 12(9):846-54. PubMed ID: 21878749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.